SEC Form 4 · accession 0001209191-15-040808
HYPERION THERAPEUTICS INC · HPTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lota S. Zoth
Director
Period of report
May 7, 2015
Accepted (ET)
May 8, 2015 · 7:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386858
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 7, 2015 | D | 2,617 | $46.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.28 | May 7, 2015 | D | 11,855 | D | — | Nov 2, 2019 | Common Stock | 11,855 | 0 | D |
| Stock Option (Right to Buy)F2 | $7.31 | May 7, 2015 | D | 4,105 | D | — | Apr 15, 2022 | Common Stock | 4,105 | 0 | D |
| Stock Option (Right to Buy)F2 | $24.46 | May 7, 2015 | D | 14,700 | D | — | Apr 14, 2023 | Common Stock | 14,700 | 0 | D |
| Stock Option (Right to Buy)F2 | $26.97 | May 7, 2015 | D | 4,869 | D | — | May 26, 2024 | Common Stock | 4,869 | 0 | D |
| Stock Option (Right to Buy)F3 | $327.95 | May 7, 2015 | D | 55 | D | — | Mar 31, 2018 | Common Stock | 55 | 0 | D |
Explanation of responses
- F1Restricted stock units covering shares of issuer common stock that will be cashed-out and cancelled in connection with the merger of the issuer and Horizon Pharma plc (the "Merger").
- F2Options to acquire shares of issuer common stock that will be cashed-out and cancelled in connection with the Merger.
- F3Options to acquire shares of issuer common stock that will be cancelled for no consideration in connection with the Merger.